Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

Rheumatoid arthritis-associated interstitial lung disease (ILD) presents a paradox: it is common and a major cause of morbidity and mortality, yet continues to lack a consistent, evidence-based ...

Strong initial responses in 4 of 6 patients after many standard drugs had failed ...

Pilot study finds partial B-cell depletion restores DMARD responsiveness ...

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36Single-dose of miv-cel delivered ...

A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk.

Antirheumatic drug abatacept delayed the onset of rheumatoid arthritis for up to four years among patients at high risk of ...

Conditions like depression may not only be complications of this rheumatoid arthritis, but may also be involved in the ...

According to researchers at Semmelweis University, not only inflammation, but also sleep disorders, depression, obesity, and ...

There is good news for patients with rheumatoid arthritis. Research from Aarhus University and Aarhus University Hospital may have opened the door to an entirely new way of reducing inflammation in ...

She’d diagnosed rheumatoid arthritis dozens of times but dismissed her own symptoms and fought her eventual diagnosis. Today ...

Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...